Search

The article discusses a clinical trial, NCT06625060, evaluating the safety and efficacy of IPN10200 in preventing episodic or chronic migraines in adults. Participants with migraines will receive injections of IPN10200 to prevent migraine episodes. The study aims to determine the right dosage of IPN10200 for efficacy and safety. Participants will be monitored for up to 44 weeks, completing daily electronic migraine diaries and questionnaires. The trial is not yet recruiting participants, with an enrollment target of 641 individuals. [Extracted from the article]

A recent study conducted at the University Children's Hospital has explored the use of botulinum toxin (BoNT) in the treatment of gastrointestinal disorders in children. The researchers found that BoNT can be considered for children with achalasia, cricopharyngeal achalasia, delayed gastric emptying, anal achalasia, constipation after Hirschsprung disease corrective surgery, resistant functional constipation, and chronic anal fissure. The study suggests that BoNT may be a viable option for improving surgical outcomes and treating these conditions in selected pediatric patients. Further information on this research can be found in the Journal of Pediatric Gastroenterology and Nutrition. [Extracted from the article]

A recent study conducted by Yonsei University College of Dentistry in Seoul, South Korea, examined the immunogenicity of botulinum toxin type A in different clinical and cosmetic treatments. The study found that while the overall incidence of neutralizing antibody formation with botulinum toxin type A treatment is relatively low, it varies depending on the indication and is influenced by factors such as the frequency of injections and the cumulative dose. The research highlights the need for further investigation into antibody formation mechanisms and the development of strategies to minimize their impact on treatment efficacy. For more information, the full article can be accessed through the provided link. [Extracted from the article]

A recent study conducted by Nanjing Medical University in Huai'an, China, has found that Botulinum toxin A (BTX-A) therapy is an effective treatment for Hemifacial Spasm (HFS), a condition characterized by involuntary muscle contractions in the face. The study involved 65 HFS patients and 65 healthy controls, and it used the Cornell Medical Index (CMI) self-assessment questionnaire to evaluate the psychological health of the participants. The results showed that BTX-A not only alleviated the symptoms of HFS but also improved somatization, tension, anxiety, depression, and sensitivity. This research provides valuable insights into the physical and mental health effects of BTX-A therapy for HFS patients. [Extracted from the article]

A recent study conducted at Osijek University Hospital Center in Croatia explored the effects of botulinum toxin therapy on eye movements and non-motor symptoms in patients with cervical dystonia (CD). The study found that memory-guided saccades, depression, and anxiety significantly improved after the administration of botulinum toxin type A (BoNT/A). CD is a condition characterized by involuntary activity of cervical muscles and is often accompanied by various non-motor symptoms. This research suggests that BoNT/A may have a central effect on CD and provides valuable insights into the potential benefits of this therapy. [Extracted from the article]

This document is a patent application for a method of purifying a Clostridium botulinum toxin complex protein. The method involves several steps, including culturing the Clostridium botulinum strain, isolating the toxin protein, and performing chromatography to purify the protein. Acid precipitation and filtration treatments are also used in the purification process. The patent application provides detailed information on the specific conditions and techniques used in each step. The purified protein has potential applications in the development of drugs and therapies for various medical conditions. [Extracted from the article]

A new report from researchers at the Aravind Eye Hospital and Postgraduate Institute of Ophthalmology in Tamil Nadu, India, explores the effectiveness of botulinum toxin A (BTX-A) in treating acute acquired comitant esotropia (AACE) in children and young adolescents. The study found that BTX-A therapy showed efficacy in treating esotropia, with over half of the patients achieving optimal outcomes and improvements in stereopsis and sensory fusion. Early intervention within three months of symptom onset was found to significantly correlate with treatment success. The study highlights the importance of patient-specific considerations and close follow-up to monitor residual and recurrence of esotropia, with surgical intervention potentially increasing the final success rate. [Extracted from the article]

MingMed Biotechnology, a company focused on drug development, has received FDA approval for its Investigational New Drug (IND) application for YY003, the world's first liquid formulation of recombinant Botulinum Toxin Type A (BoNT/A). The liquid formulation, packaged in a pre-filled syringe, is intended for the treatment of glabellar lines. Claruvis Pharmaceutical, a subsidiary of MingMed Biotechnology, has completed Phase III clinical trials for the treatment of medium to severe glabellar lines and has achieved positive results. The company has also started a Phase II clinical trial for the treatment of adult upper arm spasm in China. This approval is seen as a significant milestone in the botulinum toxin market. [Extracted from the article]

A recently published patent application outlines a method for purifying a non-complex Clostridium botulinum neurotoxin protein. This protein is commonly used for therapeutic and cosmetic purposes. The method involves loading a solution containing the toxin protein onto a hydrophobic interaction column to capture the toxin and remove impurities. The captured toxin is then isolated to obtain a purified eluent. The non-complex neurotoxin protein is obtained from the eluent and further purified using an anion exchange resin column. The patent application provides detailed information about the purification process and the characteristics of botulinum toxin proteins. The resulting purified neurotoxin protein has a purity of 98% or more. [Extracted from the article]

A recent case study conducted at the Jewish General Hospital in Quebec, Canada, explores the treatment of osmotic demyelination syndrome (ODS), a rare complication resulting from the rapid correction of severe chronic hyponatremia. The study focuses on the use of intramuscular botulinum toxin injections to target spasticity in ODS patients. The case study describes a 40-year-old male with a history of panhypopituitarism who experienced significant improvement in his condition, including reduced spasticity and regained ability to ambulate with assistance, after receiving the botulinum toxin injections. The study highlights the limited treatment options available for ODS and suggests that botulinum toxin injections may be a potential alternative for managing ODS-related spasticity that is unresponsive to other treatments. [Extracted from the article]

Researchers at the Federal University of Paraiba in Brazil have reported on a case of trigeminal neuralgia (TN) that was successfully treated with botulinum toxin type A. TN is a headache characterized by intense pain in the facial region, and it can be caused by structural mechanisms such as vascular compression of the trigeminal nerve root. In this case, the patient had TN secondary to basilar invagination (BI) and vascular compression, which had a significant impact on their quality of life. Treatment with botulinum toxin type A was effective in managing the patient's pain. The study highlights the therapeutic success of this treatment in a complex and refractory case of pain syndrome. [Extracted from the article]

This patent application discusses the development of pharmaceutical compositions containing Clostridial toxins, specifically botulinum toxin, for medical applications. The inventors propose a composition that includes a Clostridial toxin active ingredient, along with various excipients such as trehalose, poloxamer 188, polysorbate 20, L-methionine, N-acetyl-cysteine (NAC), and EDTA. These compositions are stable and suitable for injection, and the patent application also includes methods for making them and their potential use in treating depression and cardiac arrhythmia. The application aims to address the challenges associated with formulating and handling Clostridial toxin pharmaceutical compositions. [Extracted from the article]

A researcher from Tanta University in Egypt has conducted a study on the use of botulinum toxin therapy to manage salivary gland dysfunction caused by radiotherapy. The study involved injecting botulinum toxin into the salivary glands of rats before exposing them to radiation. The results showed that the botulinum-injected glands had better acinar architecture compared to the saline group, indicating that botulinum neurotoxin protected the salivary gland cells from the effects of radiation. This research suggests that botulinum toxin therapy could be an effective treatment for radiotherapy-induced salivary gland dysfunction. [Extracted from the article]

This document provides information about a Phase 3 clinical study conducted by Cutia Therapeutics(Wuxi)Co.,Ltd. The study aims to evaluate the effectiveness, safety, and immune response of CU-20101, a botulinum toxin type A, in treating moderate to severe glabellar lines. The study consists of two parts: a controlled study comparing CU-20101 with Botox, and an open-label study evaluating repeated injections of CU-20101. The study is currently recruiting participants in China and is projected to be completed by March 1, 2026. Contact details and eligibility criteria for participants are provided. [Extracted from the article]

This article provides information about a newly launched clinical trial, NCT06584240, which aims to evaluate the safety and efficacy of a recombinant botulinum toxin type A (JHM03) in adult patients with upper limb spasticity. The study will compare the effectiveness and safety of JHM03 with a placebo in this patient population. The trial is currently in the recruitment phase and is expected to be completed by February 2026. The article also includes details about the trial's design, eligibility criteria, and contact information for the primary investigator. [Extracted from the article]

This document provides a summary of a clinical trial being conducted at Cairo University. The trial, NCT06577285, aims to study the effect of botulinum toxin A in patients with excessive gingival display. Participants who meet the inclusion criteria will undergo initial therapy, periodontal treatment, and mechanical plaque control. The intervention groups will receive zinc and phytase supplementation before the botulinum toxin injections, while the control group will only receive the injections. The trial will measure various factors such as gingival display, patient satisfaction, electrical activity of smile muscles, smile type, and esthetics. The study is currently recruiting participants and is expected to be completed by June 2025, with researchers from Cairo University leading the study. [Extracted from the article]

This document provides information on a clinical trial investigating the use of Botulinum Neurotoxin-A (BoNT-A) injections in children with diplegic spastic Cerebral Palsy (CP). The trial aims to assess the impact of BoNT-A injections on pain and Selective Motor Control (SMC) in children with CP. The study will use various outcome measures to evaluate the effects of BoNT-A therapy, including pain sensation and motor function. The trial is currently recruiting participants in Turkey and aims to provide valuable insights into the potential benefits of BoNT-A therapy for children with diplegic spastic CP. [Extracted from the article]

A recent study conducted by researchers at Thammasat University in Thailand has found that botulinum toxin A (BoNT-A) injection shows promise as an effective therapy for nail psoriasis. The study compared the efficacy of BoNT-A injection, triamcinolone acetonide (TA) injection, topical combination of vitamin D/steroid (VitD/steroid), and placebo in improving nail psoriasis. The results showed that BoNT-A injection led to a 40% reduction in the total target nail psoriasis severity index (NAPSI) score at 24 weeks, with no serious adverse effects reported. The researchers concluded that BoNT-A injection could provide sustained efficacy for up to 6 months with a single injection. [Extracted from the article]

A recent study conducted by researchers from the Buddhist Tzu Chi Medical Foundation and Tzu Chi University in Hualien, Taiwan, explored the use of botulinum toxin A (BoNT-A) injections in the treatment of dysfunctional voiding (DV) in women. DV refers to abnormal urethral sphincter activity during voiding in individuals without neurological conditions. The study found that urethral sphincter denervation or reinnervation activity was commonly observed in women with DV. BoNT-A injections into the urethral sphincter provided effective treatment in nearly half of the patients, with mild improvement in urinary flow rate observed in those with reinnervation. However, the improvement was not superior to those without reinnervation. This research sheds light on the potential benefits and limitations of BoNT-A therapy for DV in women. [Extracted from the article]

The article focuses on botulinum toxin therapy for treating gummy smiles. Topics include increased demand for non-invasive treatments; a clinical trial comparing injection sites (Yonsei point vs. levator labii superioris alaeque nasi muscle); and findings that both sites effectively reduced gingival exposure and improved patient satisfaction.

The article reviews the potential therapeutic effects of botulinum neurotoxins on cancer cells, summarizing both in vitro and in vivo studies. It highlights that while botulinum toxin has shown some promise in disrupting cancer cell progression and inducing apoptosis, its potency against non-neuronal cells is much lower than against primary neurons. Topics include botulinum toxin therapy, cancer cell treatment, and advancements in delivery methods.

A new study from Saint-Chamond, France, examines the use of botulinum toxin therapy in the treatment of acquired deforming hypertonia (ADH) in older patients. The study found that botulinum toxin injections (BTxis) were effective in providing comfort for older patients with ADH, although no functional goals were achieved. The study included 41 patients over the age of 70, most of whom lived in institutions and had significant morbi-mortality. The research suggests that BTxis have the potential to meet the needs of a larger number of older patients with ADH. [Extracted from the article]

The article discusses a new clinical trial, aimed at evaluating the effectiveness of early botulinum toxin administration for closing open abdomens. Topics discussed include the trial's design and objectives, the anticipated benefits of botulinum toxin, and the current status and expected outcomes of the study.

The article reports on a study from the University of Arizona in U.S., evaluating the effectiveness of a step-up treatment approach for neurogenic cough, a persistent cough not responsive to standard therapies. It outlines the use of neuromodulators, cough suppression therapy, superior laryngeal nerve blocks, and laryngeal botulinum toxin injections, demonstrating significant improvement in a majority of patients.

A recent study conducted at the Swiss Federal Institute of Technology Zurich (ETH) explored the feasibility of using a robotic hand orthosis as an adjunct therapy after botulinum toxin injections in individuals with upper-limb spasticity. The study involved five participants who received botulinum toxin injections and then engaged in a simulated unsupervised therapy session with the robotic hand orthosis. The results showed a reduction in muscle tone and functional improvements in the participants. The researchers concluded that the addition of the robotic hand orthosis therapy was safe and had the potential to enhance therapy doses and long-term outcomes. [Extracted from the article]

The article reports on a clinical trial comparing the efficacy and safety of microneedling combined with Botulinum Toxin-A versus meso-Botox injection for treating atrophic acne scars. Topics include the use of Micro-Botox for skin improvement, the methodology of the split-face study design, and the trial's recruitment status and eligibility criteria.

A patent application has been filed for a new method of treating headaches, specifically migraines, using neurotoxins. The current FDA-approved treatment, BOTOX, can have side effects such as muscle weakness and involves multiple injections. The new method aims to simplify the injection process and reduce side effects by targeting specific nerve pathways involved in migraines. The patent application outlines various injection sites and combinations that can be used to enhance the treatment's effectiveness. By avoiding certain areas, the occurrence and severity of side effects can be reduced. The inventors claim that their methods can provide more effective and targeted treatment for migraines and headaches. [Extracted from the article]

A recent study conducted at Rio Hortega University Hospital in Valladolid, Spain, explored the use of botulinum toxin type A (BoNT-A) for treating post-stroke spasticity (PSS). The researchers used natural language processing and machine learning to analyze data extracted from electronic health records (EHRs) of patients in five Spanish hospitals. The study found that 25.5% of patients with PSS received BoNT-A, primarily for pain relief, about one year after their stroke. The researchers emphasized the importance of early treatment, disease monitoring, and better documentation in EHRs to improve care for PSS patients. [Extracted from the article]

The article covers the publication of a patent application for innovative packaging and formulation systems designed for neurotoxins, including botulinum toxins, to reduce waste and treatment costs while improving safety and usability. It states that the application introduces single-use packaging solutions and color-coded components for precise dosage and reduced neurotoxin waste.

The article reports on the patent application filed for novel pharmaceutical compositions utilizing non-protein excipients to stabilize Clostridial toxins, such as botulinum toxin, in medical formulations. It focuses on addressing stability issues of these toxins by substituting traditional protein-based stabilizers with non-protein alternatives to ensure safety, efficacy, and ease of use.

A recent report from Emory University in Atlanta, Georgia discusses the use of functional lumen imaging probe (FLIP) topography data to select patients with esophagogastric junction outflow obstruction (EGJOO) who would benefit from lower esophageal sphincter botulinum toxin (Botox) injection. The study found that a spastic-reactive FLIP contractile response (CR) pattern was the best predictor of a positive response to Botox treatment. The research suggests that FLIP can help identify patients with EGJOO who are likely to respond to Botox therapy. This information may be useful for individuals seeking treatment for EGJOO. [Extracted from the article]

A recent report from Tokyo, Japan discusses the use of botulinum toxin therapy (BoNT-A) combined with rehabilitation as a treatment for lower-limb spasticity. The report highlights the improvements in spasticity, joint motion, and pain reduction that have been observed with BoNT-A therapy. The researchers emphasize the importance of a multifaceted approach to spasticity assessment, administration, and rehabilitation in order to optimize the effects of BoNT-A and achieve functional improvement and gait reconstruction. They suggest that BoNT-A treatment should be established as a therapeutic strategy for improving walking function in addition to treating spasticity. [Extracted from the article]

A patent application titled "Treatment Of Acute Heart Failure Using Nitrous Oxide And Chronic Heart Failure Using Botulinum Toxin" has been published online. The application describes methods for treating acute and chronic heart failure by targeting the cytokine system, which plays a role in the pathology of these conditions. The methods involve administering botulinum toxin to mitigate chronic inflammation and loss of heart tissue, and using nitrous oxide and oxygen inhalation to control acute cytokine damage. The patent application provides specific details on the administration of these treatments. [Extracted from the article]